Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Portfolio Pulse from
Eupraxia Pharmaceuticals reported positive results from the fifth cohort of its RESOLVE Phase 1b/2a trial for EP-104GI, a treatment for Eosinophilic Esophagitis. One patient achieved complete histological remission, and all evaluable patients in the recent cohorts showed symptom improvement.
November 12, 2024 | 11:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eupraxia Pharmaceuticals announced positive trial results for EP-104GI, with one patient achieving complete remission and all showing symptom improvement, potentially boosting investor confidence.
The positive trial results, including complete remission in one patient and symptom improvement in all, are likely to boost investor confidence in Eupraxia Pharmaceuticals, potentially leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100